WE CLAIM:

1. A stable pharmaceutical composition comprising a core, wherein the core includes rabeprazole and at least 10% w/w of low viscosity hydroxypropylcellulose.

2. The stable pharmaceutical composition according to claim 1, wherein the core further comprises an antioxidant.

3. The stable pharmaceutical composition according to claim 1, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.

4. The stable pharmaceutical composition according to claim 3, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 50 m. Pas to about 200 m. Pas.

5. The stable pharmaceutical composition according to claim 2, wherein antioxidant comprises one or both of butylated hydroxy toluene and butylated hydroxy anisole.

6. The stable pharmaceutical composition according to claim 5, wherein the antioxidant comprises from about 0.02% to about 0.2% by weight of the total core weight.

7. The stable pharmaceutical composition according to claim 1, wherein the core further comprise polyvinylpyrrolidone.

8. The stable pharmaceutical composition according to claim 7, wherein the average molecular weight of the polyvinylpyrrolidone ranges from about 10,000 to about 360,000.

9. The stable pharmaceutical composition according to claim 8, wherein the average molecular weight of polyvinylpyrrolidone ranges from about 40,000 to about 60,000.

10. The stable pharmaceutical composition according to claim 7, wherein the polyvinylpyrrolidone comprises from about 0.5% to about 5% by weight of the total core weight.

11. The stable pharmaceutical composition according to claims 1, wherein the core is selected from the group consisting of tablet, granule and capsule.

12. The stable pharmaceutical composition according to claim 11 wherein the core is a tablet.

13. The stable pharmaceutical composition according to claim 1, wherein the core is coated with a subcoat layer and an enteric coat layer.

14. The stable pharmaceutical composition according to claim 13, wherein the subcoat layer comprises one or more film forming agents.

15. The stable pharmaceutical composition according to claim 14, wherein the one or more film forming agents comprises one or more of microcrystalline cellulose, carageenan, ethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, polyethylene glycol, polyvinyl alcohol and xanthan gum.

16. The stable pharmaceutical composition according to claim 15, wherein the film-forming agent comprises hydroxypropyl methylcellulose.

17. The stable pharmaceutical composition according to claim 13 wherein the subcoat layer includes an antioxidant.

18. The stable pharmaceutical composition according to claim 13, wherein the enteric coat layer comprises one or more enteric polymers.

19. The stable pharmaceutical composition according to claim 18, wherein the enteric polymer comprises one or more of cellulose acetate phthalate, hydroxypropyl methylcellulose acetate phthalate, polyvinyl acetate phthalate, hydroxy propyl phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate; and methacrylic acid copolymers.

20. The stable pharmaceutical composition according to claim 19, wherein the enteric polymer comprises hydroxypropyl methylcellulose phthalate.

21. The stable pharmaceutical composition according to claim 13, wherein one or more of the core, the subcoat layer, and the enteric layer further comprise pharmaceutically acceptable inert excipients.

22. The stable pharmaceutical composition according to claim 21, wherein the one or more pharmaceutically acceptable inert excipients are selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.

23. A process for preparing a stable pharmaceutical composition comprising a core, the process comprising:

preparing a core by

(i) blending rabeprazole and a low viscosity hydroxypropylcellulose to form a blend, and

one or both of (ii) granulating the blend and (iii) compressing the blend to form a compact mass core, wherein the low viscosity hydroxypropylcellulose comprises at least 10% w/w of the core.

24. The process of claim 23, further comprising coating the core with one or both of a subcoat layer and an enteric coat layer.

25. The process of claim 23, further comprising blending one or more antioxidants with the rabeprazole and low viscosity hydroxypropylcellulose.

26. The process according to claim 25, wherein the antioxidant is adsorbed over a diluent.

27. The process according to claim 23, wherein the core is selected from the group consisting of tablet, granule and pellet.

28. The process according to claim 27, wherein the core comprises a tablet.

29. The process according to claim 23, wherein the core is prepared by one or more of a wet granulation method, a dry granulation method, or a direct compression method.

30. The process according to claim 29, wherein the core is prepared by direct compression method.

31. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied as a solution/suspension.

32. The process according to claim 31, wherein the solution/suspension is prepared in solvents selected from the group consisting of methylene chloride, isopropyl alcohol, acetone, methanol, ethanol, water and mixtures thereof.

33. The process according to claim 24, wherein one or both of the subcoat layer and the enteric coat layer are applied using a hot melt technique.

34. The process according to claim 24, wherein one or more of the core, the subcoat layer, and the enteric coat layer contains one or more pharmaceutically acceptable inert excipients.

35. The process according to claim 34, wherein the one or more pharmaceutically acceptable inert excipients is selected from the group consisting of binders, disintegrants, lubricants, glidants, diluents, plasticizers, opacifiers, and coloring agents.

36. The process according to claim 24, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.

37. A method of treating digestive ulcers in a mammal by administering to the mammal a stable pharmaceutical composition of rabeprazole, wherein the composition includes a core comprises rabeprazole and at least 10% w/w of low viscosity hydroxypropyl cellulose.

38. The method of treating of claim 37, wherein the viscosity of the low viscosity hydroxypropylcellulose ranges from about 5 m. Pas to about 300 m. Pas.

39. The method of treating of claim 37, wherein the core further comprises an antioxidant.